Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma

Dávila González I1, Moreno Benítez F2, Quirce S3

1Allergy Service, University Hospital of Salamanca, School of Medicine, University of Salamanca, Salamanca, Spain
2Immunology and Allergy Unit, Clínica Lobatón, Cádiz, Spain; Grupo Asociado AS03 Inmunología y Alergia, associated with IN–CO16 INIBICA (Instituto Biomédico de Cádiz), Cádiz, Spain
3Department of Allergy, Hospital Universitario La Paz Institute for Health Research (IdiPAZ) and CIBER of Respiratory Diseases (CIBERES), Madrid, Spain

Abstract

Eosinophilic asthma is the most common phenotype of severe asthma. It is characterized by abnormal production and release of type 2 cytokines from T helper type 2 (Th2) lymphocytes and type 2 innate lymphoid cells, such as IL-5. This leads to a persistent increase and activation of eosinophils in blood and the airways despite treatment with high-dose inhaled corticosteroids. Eosinophil differentiation, survival, and activation are preferentially regulated by IL-5, a cytokine that binds to the IL-5 receptor (IL-5R), which is located on the surface of eosinophils or basophils and plays a critical role in the pathogenesis and severity of asthma. Benralizumab is a monoclonal antibody that binds to IL-5R via its Fab domain, blocking the binding of IL-5 to its receptor and resulting in inhibition of eosinophil differentiation and maturation in bone marrow. In addition, this antibody is able to bind through its afucosylated Fc domain to the RIIia region of the Fcγ receptor on NK cells, macrophages, and neutrophils, thus strongly inducing antibody-dependent, cell-mediated cytotoxicity in both circulating and tissue-resident eosinophils. This double function of benralizumab induces almost complete fast and maintained depletion of eosinophils that is much greater than that induced by other monoclonal antibodies targeting the IL-5 pathway, such as mepolizumab and reslizumab. This review focuses on benralizumab as an alternative to other agents targeting the IL-5 pathway in the treatment of eosinophilic asthma.

Key words: Eosinophils. Basophils. ILC-2. Exacerbations. Phenotype.
1. Introduction

According to the Global Initiative for Asthma (GINA), asthma is a heterogeneous disease that is usually characterized by chronic airway inflammation and defined by respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough, which vary over time and in intensity, together with variable expiratory airflow limitation [1]. Variations are often triggered by factors such as exercise, allergen or irritant exposure, changes in weather, and viral respiratory infections [2]. Moreover, asthma is considered a heterogeneous syndrome resulting from complex interactions between environmental and genetic factors. These interactions result in very diverse clinical presentations and phenotypes [3].

The main features of asthma include airway inflammation and remodeling, bronchial obstruction, airway hyperresponsiveness, and variation or fluctuation in symptoms and lung function over time [2]. Even if the clinical spectrum of asthma is highly variable, inflammation of the airways is a common pathological feature, although the relationship between the severity of asthma and the intensity of inflammation has not been consistently established [4]. In most asthmatic patients, the characteristic inflammatory pattern includes an increase in the number of type 2 helper T (T_{H2}) lymphocytes, type 2 innate lymphoid cells (ILC-2s), and natural killer (NK) cells, as well as mast cells, basophils, and activated eosinophils, which release mediators that cause symptoms of disease [5,6].

Type 2 immune reactions are categorized as adaptive immune responses with differentiated T_{H2} cells taking center stage, driving eosinophil recruitment and immunoglobulin production via secretion of a distinct repertoire of cytokines that include interleukin (IL) 4, IL-5, and IL-13. In addition, ILC-2s have the capacity to secrete type 2 cytokines in the absence of adaptive immunity. These cells respond to stress signals and to the so-called alarmins, ie, IL-33, IL-25, and thymic stromal lymphopoietin, which drive ILC-2 growth and cytokine production. In some types of asthma, eosinophilic inflammation is controlled by these cells, which act together with basophils [7,8].

Severe asthma is characterized by the need for treatment with several drugs at high doses and can be controlled and uncontrolled [9]. Severe uncontrolled asthma is defined as asthma that continues to be poorly controlled despite treatment with a combination of high-dose inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs) and/or other controller drugs [10]. Moreover, asthma is considered a heterogeneous syndrome resulting from complex interactions between environmental and genetic factors. These interactions result in very diverse clinical presentations and phenotypes [3].

The prevalence of uncontrolled severe persistent asthma has been estimated at least 6 months during the same period [10]. The prevalence of uncontrolled severe persistent asthma is characterized by abnormal production of type 2 cytokines produced by T_{H2} lymphocytes and ILC-2s, resulting in a persistent increase in eosinophils in blood and the airways (sputum, bronchoalveolar lavage, and bronchial mucosa or submucosa) [29-31]. Blood and sputum eosinophilia have been associated with more severe disease, worse disease control, and a higher risk of exacerbations [32].

2. Characteristics and Treatment of Eosinophilic Asthma

Eosinophilic asthma is the most common asthmatic phenotype, accounting for over 50% of cases of severe asthma. It is characterized by abnormal production of type 2 cytokines produced by T_{H2} lymphocytes and ILC-2s, resulting in a persistent increase in eosinophils in blood and the airways (sputum, bronchoalveolar lavage, and bronchial mucosa or submucosa) [29-31]. Blood and sputum eosinophilia have been associated with more severe disease, worse disease control, and a higher risk of exacerbations [32].

Severe eosinophilic asthma should fulfill the diagnostic criteria for severe asthma and demonstrate a persistent increase in eosinophils in blood and/or the airways [31]. Although there is no consensus on eosinophil cut-off levels, a blood eosinophil count of 0.22-0.27×10^9/L is used to differentiate between eosinophilic and noneosinophilic asthma with a sensitivity of 78%-86% [33]. Elevated blood eosinophil levels are associated with decreased lung function parameters (forced expiratory volume in 1 second [FEV₁] and peak expiratory flow [PEF]) [34]. In addition, increased blood eosinophil counts (0.3×10^9/L), along with increased fractional exhaled nitric oxide (FeNO) levels, are associated with more poorly controlled asthma [35]. Furthermore, elevated blood eosinophil counts (>0.4×10^9/L) are correlated with sputum eosinophils in mild to severe asthma and linked to a higher rate of severe asthma exacerbations [36,37]. A recent report has shown that blood eosinophilia has good sensitivity but low specificity for detection of eosinophilia in sputum, even in patients treated with inhaled corticosteroids, in contrast with FeNO, whose sensitivity decreases in patients treated with corticosteroids [38].

Eosinophils represent approximately 1%-5% of peripheral blood leukocytes. They are produced in bone marrow, and their differentiation, survival, and activation are mainly regulated by IL-5 [39,40]. However, it has been suggested that local differentiation, maturation, and activation of eosinophils in the airways may contribute to persistent sputum eosinophilia in prednisone-dependent patients who may have normal blood eosinophil counts. This local event may be driven by IL-5 and IL-13, which are produced locally by relatively corticosteroid-
Benralizumab in Eosinophilic Asthma

Eosinophils have different functions, such as tissue repair and remodeling, angiogenesis, clearance of parasites, metabolic homeostasis, immune surveillance, and immune cell activation. In addition, eosinophils and their mediators participate in the pathophysiology of a variety of diseases, including allergic asthma [39,40,42]. Although the main pathway for the recruitment of eosinophils into blood and airways includes T<sub>h</sub>2 cells and the production and release of IL-4, IL-5, and IL-13, mounting evidence suggests that other pathways and cells might contribute. Thus, ILC-2s express both IL-5 and IL-13 and are thought to be intrinsically resistant to corticosteroids [41].

By binding to the IL-5Rα chain of the IL5 receptor (IL-5R), IL-5 is a T<sub>h</sub>2 cytokine involved in the differentiation, maturation, migration, activation, and prevention of apoptosis of eosinophils [39]. In addition, IL-5 appears to mediate the development of basophils and mast cells, enhancing the release of mediators (such as leukotrienes) via the engagement of IL-4, IL-5, and IL-13, mounting evidence suggests that other pathways and cells might contribute. Thus, ILC-2s express both IL-5 and IL-13 and are thought to be intrinsically resistant to corticosteroids [41].

Biological drugs targeting either eosinophils or the IL-5 pathway have been developed for the treatment of severe uncontrolled eosinophilic asthma, irrespective of the presence of allergy. On the one hand, some biologic therapies (eg, bertilimumab) block recruitment of eosinophils, thus preventing the accumulation of these cells in tissues [46]. In addition, drugs targeting the IL-5 pathway may be used; these bind directly to IL-5 (mepolizumab and reslizumab) and to IL-5Rα (benralizumab) (Figure) [16-28]. By blocking the interaction between IL-5 and its receptor, the eosinophil count in blood and the airways decreases, as does survival of these cells, ultimately resulting in clinical improvement.

### 3. Characteristics of Benralizumab

Benralizumab is a humanized IgG1κ monoclonal antibody. It has been approved as add-on maintenance treatment in adult patients with severe eosinophilic asthma that is inadequately controlled despite high-dose ICSs plus a LABA [47]. The antibody is able to bind to IL-5Rα via its Fab domain with high affinity and specificity, thus blocking binding of IL-5 to its receptor, which is located on human eosinophils and basophils. As a result, the proliferation and maturation of these cells in bone marrow is affected, as are migration, activation, and survival at the sites of inflammation (Figure) [48]. The Administration of benralizumab produces a dramatic reduction in eosinophil counts in blood, airway mucosa, and sputum, as well as inhibition of eosinophil differentiation and maturation in bone marrow.

In contrast with the anti-IL5 monoclonal antibodies mepolizumab and reslizumab, benralizumab lacks a fucose sugar residue in the C<sub>H</sub>2 region of the Fc domain. This afucosylation enables benralizumab to bind with high affinity to the R<sub>H</sub>α region of the Fcγ receptor found on NK cells, macrophages, and neutrophils, thus strongly inducing antibody-dependent cell-mediated cytotoxicity of eosinophils and basophils (Figure) [49]. Consequently, benralizumab can target and deplete both circulating and tissue-resident eosinophils. Mepolizumab and reslizumab only block the activation of eosinophils by neutralizing circulating IL-5 without inducing apoptosis of resident eosinophils [48]. Apoptosis has the advantage of preventing the release of toxic granules.

Acting directly on a specific cell receptor instead of indirectly through a mediator enables more effective depletion of target cells. Thus, benralizumab induces fast and almost complete depletion of eosinophils (>95%), which is higher than that induced by mepolizumab (84%) and reslizumab (82%) [16-28]. This almost complete depletion of blood eosinophils occurs within 24 hours of the first dose. The effect is maintained for 12 weeks after a single dose ranging from 0.3 to 3 mg/kg [50]. The decrease in blood eosinophils is accompanied by a reduction in serum levels of eosinophil-derived neurotoxin and eosinophil cationic protein and a decrease in blood basophils. In addition, no changes were observed in levels of tumor necrosis factor and interferon gamma, whereas serum levels of IL-5, CCL11, and CCL24 were significantly higher for benralizumab than for placebo (P<.05) [51,52].

The effect of benralizumab on the eosinophils of the airway mucosa was evaluated in a 12-week, double blind, randomized, placebo-controlled phase 1 study of asthmatic patients with elevated eosinophil counts in sputum (at least 2.5%). Eighty-four days after subcutaneous administration of 100 mg or 200 mg of benralizumab, a median reduction of 95.8% in airway eosinophil counts in bronchial biopsies was observed (46.7% with placebo, P=.06), as was an 89.9%
decrease in the eosinophil count in sputum [53]. Similar results were observed more recently with the approved subcutaneous dose of benralizumab (30 mg), resulting in an almost complete depletion of eosinophils in both blood and sputum after 12 weeks of treatment [54,55].

4. Optimal Dose of Benralizumab

A pilot trial on the safety, pharmacokinetics, and biologic activity of benralizumab that assessed intravenous doses (0.0003-3 mg/kg) administered to patients with mild atopic asthma found that peripheral blood eosinophil levels decreased in a dose-dependent manner, reaching eosinopenia after 8-12 weeks with dosages >0.03 mg/kg and an acceptable safety profile [50]. In addition, a phase 1 study evaluated the safety and tolerability of benralizumab, as well as its effect on eosinophil counts in biopsies of the airway mucosa from patients with atopic asthma [53]. Twenty-seven adults with asthma and ≥2.5% of eosinophils in sputum were allocated to 2 cohorts. The first cohort received a single intravenous dose of benralizumab (1 mg/kg), and the second cohort received the drug subcutaneously (100 mg or 200 mg). After 21 days, intravenous treatment decreased the eosinophil count in sputum by 18.7%, whereas the subcutaneous dosage achieved a reduction of 89.9%. On the other hand, both treatment strategies decreased blood eosinophil counts by 100%. The authors concluded that a single intravenous dose and multiple subcutaneous dosing of benralizumab led to reduced eosinophil counts in airway mucosa/submucosa and sputum, and a suppression of bone marrow eosinophil counts, resulting in a significant reduction in eosinophilic airway inflammation compared with placebo [53].

A randomized, controlled, double-blind, dose-ranging phase 2b study assessed the efficacy and safety of benralizumab in adults with uncontrolled eosinophilic asthma despite using medium or high-dose ICSs and a LABA and 2-6 exacerbations in the previous year [56]. Eligible participants were stratified by their eosinophilic status based on the eosinophil/lymphocyte and eosinophil/neutrophil index and FeNO levels (cut-off point < or ≥50 ppb). Eosinophilic patients were randomized to receive placebo or benralizumab (2 mg, 20 mg, or 100 mg). Noneosinophilic patients received placebo or 100 mg benralizumab. Treatment was given as 2 subcutaneous injections every 4 weeks for the first 3 doses, then every 8 weeks, for 1 year. At the 100-mg dose, benralizumab was found to reduce exacerbation rates in the eosinophilic cohort by 41% (P=0.096) compared with placebo, but not at the 2-mg (P=0.781) or 20-mg (P=0.173) dose. In patients with a baseline blood eosinophil cut-off of at least 300 cells/μL, exacerbation rates were reduced by 57% in the benralizumab 20-mg group (P=0.015), and by 43% in the 100-mg group (P=0.049). The authors concluded that the dose-response plateau of benralizumab ranges between 20 mg and 100 mg. In the group of noneosinophilic patients who received 100 mg of benralizumab, the exacerbation rate was reduced by 22%, although the difference did not reach statistical significance (P=0.284) [56].

5. Efficacy Trials With Benralizumab

The efficacy and safety of benralizumab in the treatment of severe uncontrolled eosinophilic asthma was evaluated in 3 phase 3 randomized, double-blind, placebo-controlled, parallel-group clinical trials with a duration of 28-56 weeks in patients aged 12-75 years [27,28,55]. A summary of these trials is shown in Table 1. The SIROCO and CALIMA trials examined the effects of the monoclonal antibody on long-term exacerbations in both adults and adolescents (≥12 years), while the ZONDA trial evaluated the reduction in OCS use following antibody administration in adults.

In all 3 studies, patients were randomized to 3 groups. In 2 groups, benralizumab was administered at a dose of 30 mg once every 4 weeks for the first 3 doses and then every 4 or 8 weeks, respectively, for each group. The third group received placebo. Although 2 dosage regimens of benralizumab were studied in the 3 trials, the following results correspond mainly to the recommended dose of benralizumab: 30 mg every 4 weeks for the first 3 doses and then every 8 weeks [47]. No additional benefit was observed with the more frequent administration schedule (every 4 weeks) [27,28,55].

5.1. SIROCCO and CALIMA: Exacerbation Trials

The SIROCCO [28] and CALIMA [27] trials included a total of 2511 patients with severe uncontrolled asthma. The mean age of the patients was 49 years, and 64% were women. Patients had a history of ≥2 asthmatic exacerbations (between 2.7-3.0) requiring oral or systemic corticosteroids in the previous 12 months, a score ≥1.5 on the Asthma Control Questionnaire-6 (ACQ-6) at baseline, and a mean predicted prebronchodilator FEV1 of 57.5% despite regular treatment with high-dose ICSs (SIROCCO) or a combination of medium- or high-dose ICSs and a LABA (CALIMA). The primary objective of these 2 trials was the annual rate of asthma exacerbations in patients with a baseline blood eosinophil count ≥300 cells/μL who were receiving a combination of high-dose ICSs and a LABA. An exacerbation was defined as a worsening of asthma requiring oral/systemic corticosteroids for at least 3 days or emergency department visits requiring oral/systemic corticosteroid.
corticosteroids, hospitalization, or both emergency visits and hospitalization. For patients receiving oral maintenance corticosteroids, exacerbations were defined as a temporary increase in the stable dose of OCSs/systemic corticosteroids for at least 3 days or a single injectable dose of extended-release corticosteroids.

In both trials, the rate of annual exacerbations decreased significantly in patients treated with benralizumab compared with those receiving placebo when the blood eosinophil count was ≥300 cells/µL. A decrease in the rate of exacerbations was observed irrespective of the baseline eosinophil count (≥300 eosinophils/µL, reduction of 51% in SIROCCO at 48 weeks [P < .0001] or 28% in CALIMA at 56 weeks [P = .0188] relative to placebo; <300 eosinophils/µL, reduction of 17% in SIROCCO at 48 weeks [P = .269] or 40% in CALIMA at 56 weeks [P = .0048] relative to placebo).

The beneficial effect on FEV₁ could be measured from 4 weeks onwards and was maintained until the end of the treatment. The difference in least-squares mean change from baseline between the benralizumab and placebo cohorts was 0.159 L (0.068-0.249; P = .0006) in SIROCCO, 0.116 L (0.028-0.204; P = .0102) in CALIMA in patients with <300 eosinophils/µL, 0.102 L (0.003-0.208; P = .568) in SIROCCO, and –0.015 L (–0.127 to 0.096; P = .7863) in CALIMA in patients with ≥300 eosinophils/µL.

When the results of both studies were pooled, there was a numerically greater decrease in the rate of exacerbations and a greater improvement in FEV₁ when blood eosinophil count was increased at baseline. An increase in baseline eosinophil count was a possible predictor of better response to treatment, particularly for FEV₁.

The rate of exacerbations requiring hospitalization or emergency department visits in patients treated with benralizumab, compared with those receiving placebo, was 0.09 vs 0.25 (P < .001) in SIROCCO and 0.12 vs 0.10 (P = .538) in CALIMA. It is important to note that in the CALIMA study, the low number of episodes of exacerbations requiring hospitalization or emergency visits in the placebo group precludes precise conclusions. Subgroup analyses of both trials indicated that a higher incidence of previous exacerbations was a possible predictor of a better response to treatment. When considered separately or in combination with baseline blood eosinophil count, these factors may identify patients who achieve a greater response with benralizumab.

The results of both trials showed that patients treated with benralizumab experienced statistically significant decreases in asthma symptoms compared with those receiving placebo. A similar improvement was observed with benralizumab in the ACQ-6 and in Standardized Asthma Quality of Life Questionnaire for patients aged 12 years and older (AQLQ[S]+12).

Both the SIROCCO and CALIMA trials met their primary objective and mutually confirmed their respective results. The benefits of benralizumab were observed not only in the reduced frequency of asthma exacerbations, but also in improved lung function and asthma symptoms.

A post hoc subanalysis of both trials assessed the efficacy and safety of benralizumab in patients with eosinophil-driven disease and blood eosinophil counts <300 cells/µL [57]. This analysis compared an eosinophil cut-off count of ≥150 with one of <150 cells/µL. The results showed that benralizumab reduced asthma exacerbation rates by 42% in SIROCCO (P < .001) and 36% in CALIMA (P < .001) compared with placebo for patients with blood eosinophil counts ≥150 cells/µL. In addition, benralizumab increased prebronchodilator FEV₁ (in both studies, P ≤ .002) and improved the total asthma symptom score in SIROCCO (P = .009) at the end of treatment compared with placebo. The authors concluded that benralizumab is clearly effective in patients with asthma and blood eosinophil counts ≥150 cells/µL [57].

Another pooled analysis of results from the SIROCCO and CALIMA trials compared the annual exacerbation rate ratio with placebo in subgroups defined by baseline eosinophil counts (≥0, ≥150, ≥300, and ≥450 cells/µL) and by number of exacerbations (2 vs ≥3) during the year before enrollment [58]. The annual exacerbation rate among patients with baseline blood eosinophil counts ≥90 cells/µL was 1.16 in patients who received placebo compared with 0.75 in patients who received benralizumab. The reduction rate was greater with increasing blood eosinophil thresholds and with higher numbers of exacerbations. A very recent pooled analysis of the SIROCCO and CALIMA trials evaluated the impact of baseline factors on the efficacy of benralizumab for patients with severe asthma [59]. The results showed that the effect of benralizumab (reduced exacerbation rate, improved lung function, and improved asthma symptoms and control) was enhanced in the overall population and in patients with a baseline eosinophil count ≥300 cells/µL and the following clinical factors: OCS use, nasal polyposis, prebronchodilator forced vital capacity (FVC) < 65% of predicted, ≥3 exacerbations in the previous year, and age at diagnosis ≥ 18 years. In patients with <300 cells/µL, OCS use, nasal polyposis, and FVC < 65% of predicted, the response to benralizumab was better and the exacerbation rate lower. The results of these pooled analyses can help to identify those patients with uncontrolled severe eosinophilic asthma who respond most effectively to benralizumab.

5.2. ZONDA: Oral Corticosteroid Reduction Trial

The ZONDA trial included 220 patients with severe asthma associated with eosinophilia and treated with oral corticosteroids [55]. Patients received 8-40 mg/d of OCS and a regular combination of high-dose ICSs and a LABA, with at least 1 additional drug to maintain asthma control in 53% of cases. Mean age was 51 years, and 61% were women. The trial had an 8-week preinclusion period in which OCSs were adjusted to the minimum effective dose without losing asthma control. Patients had a blood eosinophil count ≥150 cells/µL and a history of at least 1 exacerbation in the previous year. The primary objective of this trial was the percent decrease in the final dose of OCS during weeks 24 to 28 from baseline while maintaining asthma control.

At week 28, benralizumab significantly reduced the median final OCS doses from baseline by 75%, as compared with a reduction of 25% in the placebo group (P < .001). Moreover, benralizumab administered every 4 weeks resulted in an annual exacerbation rate that was 55% lower than that of placebo (P = .003), and benralizumab administered every 8 weeks resulted in an annual exacerbation rate that was 70%
lower than that of placebo ($P<.001$). However, lung function (FEV1) was not significantly improved in the active treatment group, as compared with the placebo group. Of note, asthma control and health-related quality of life were better in the benralizumab 8-week dosing regimen ($P<.05$ vs placebo), but not for the 4-week regimen. With respect to the secondary endpoints in patients who per protocol reached 0 in their dose of OCS (baseline dose ≤12.5 mg of prednisone), 52% of patients in the 8-week dosing group managed to eliminate systemic corticosteroids, compared with only 19% in the placebo group. In addition, 59% of patients managed to maintain an OCS dose ≤5 mg/d. In conclusion, patients with severe eosinophilic asthma who received benralizumab subcutaneously every 8 weeks were able to reduce the use of OCS as maintenance treatment while maintaining asthma control [55].

6. Safety of benralizumab

The first safety data reported are from a phase 1 trial that evaluated the safety, tolerability, and effects of benralizumab (administered as single-dose intravenous or multiple-dose subcutaneous injections) on eosinophil counts in airway mucosal biopsies of patients with atopic asthma [53]. The incidence of adverse events (AEs) was found to be higher in the benralizumab group than in the placebo group for intravenous dosing (27 vs 17 events, respectively) but not in the multiple subcutaneous dosing group (10 vs 15 vs 20 events in benralizumab 100 mg, benralizumab 200 mg, and placebo, respectively) [53]. Of note, at least 1 AE was reported in 100% of patients who received placebo and in approximately 60% in the benralizumab group. It could be concluded that none of the AEs reported in this trial seemed to be clearly associated with treatment. In a phase 2b dose-ranging study, all AEs and all serious AEs were equally distributed between the placebo and benralizumab groups [56]. Nasopharyngitis was reported by 11% of patients receiving benralizumab vs 6% in the placebo group, and injection site reactions occurred in 16% of patients receiving benralizumab and 4% receiving placebo.

| Table 2. Most Frequent Adverse Reactions During Treatment With Benralizumab 30 mg Every 8 Weeks in Patients With Severe Uncontrolled Eosinophilic Asthma |
|---------------------------------------------------------------|--------------|-------------------|-------------------|
| Worsening asthma                                              | SIROCCO [28] | CALIMA [27]       | BORA [60]         |
|                                                               | PCB          | B                 | PCB               |
| Nasopharyngitis                                               | 19%          | 11%               | 15%               |
| Upper respiratory tract infection                             | 9%           | 8%                | 9%                |
| Headache                                                     | 5%           | 9%                | 7%                |
| Bronchitis                                                   | 7%           | 5%                | 12%               |
| Sinusitis                                                    | 7%           | 6%                | 8%                |
| Influenza                                                    | 6%           | 5%                | 5%                |
| Pharyngitis                                                  | 3%           | 6%                | 2%                |
| Injection site reactions                                     | 2%           | 2%                | 2%                |

Abbreviations: B, benralizumab; PCB, placebo

With respect to the phase 3 trials SIROCCO and CALIMA, the number of AEs and serious AEs did not differ between the placebo and treatment arms. The most frequently reported AEs during treatment with 30 mg of benralizumab every 8 weeks were nasopharyngitis (12-18%), worsening asthma (11%), upper respiratory tract infection (8%), and headache (8-9%) [27,28]. Table 2 shows a comparison of the most common AEs in each study.

The presence of antidrug antibodies was detected in 13% (SIROCCO) and 15% (CALIMA) of the patients who received the recommended dosage of benralizumab [27,28]. Most of these antibodies were neutralizing and persistent. Although clearance of benralizumab and the amount of eosinophils in blood was greater in those patients with elevated antidrug antibody titers than in patients without these antibodies, there was no suggestion that positive antidrug antibody response was associated with hypersensitivity or affected efficacy outcomes [27,28].

According to the SIROCCO, CALIMA, and ZONDA studies, the rate of hypersensitivity reactions in patients receiving benralizumab did not differ from that reported for patients receiving placebo. In the SIROCCO trial, the frequency of hypersensitivity reactions was 3% in both the treated group and the control group; in the CALIMA trial it was 4% for those who received placebo and 3% for those who received the recommended dose of benralizumab; and in the ZONDA trial, it was 3% for those who received the biological drug and 1% for those who received placebo [27,28,55].

The BORA extension study is a recent randomized, double-blind, parallel-group, phase 3 extension trial that assessed the long-term safety profile of benralizumab in patients with severe, uncontrolled eosinophilic asthma [60]. All patients who previously participated in and completed the SIROCCO, CALIMA, or ZONDA trials were eligible for enrolment in the BORA study, although the publication only included data from the SIROCCO and CALIMA trials, as the ZONDA study had a different design, was shorter, and had a smaller study population than SIROCCO and CALIMA. Eligible patients had to have completed both trials and remained on subcutaneous
benralizumab 30 mg every 4 or 8 weeks. Patients who had received placebo were rerandomized at a 1:1 ratio to benralizumab 30 mg every 4 weeks or every 8 weeks. The full analysis set included 1576 patients: 783 who received benralizumab every 4 weeks (including 265 newly assigned patients) and 793 who received benralizumab every 8 weeks (including 281 newly assigned patients). After 1 year of treatment, the most common adverse events in both treatment groups that led to treatment discontinuation were viral upper respiratory tract infection (14%-16%) and worsening asthma (7%-10%), and the most common serious AEs were worsening asthma (3%-4%) and pneumonia (≤1%). The percentage of patients who received benralizumab and who experienced an AE was similar between SIROCCO or CALIMA (71%-75%) and BORA (65-71%), as was the percentage of patients who had an AE that led to treatment discontinuation (2% in SIROCCO and CALIMA vs 2-3% in BORA). The results of the BORA study support the administration of benralizumab for 2 years, with a safety and tolerability profile similar to that observed over 1 year in the SIROCCO and CALIMA trials.

Although elimination of eosinophils due to anti–IL-5 treatment may have some impact on host defense (eg, against parasitic infections), further studies and clinical observation in this area are needed, as patients with known helminthic infections were excluded from participation in clinical trials. Nevertheless, no cases of helminth infection were reported in the BORA study [60].

### Table 3. Ongoing Phase III Studies With Benralizumab

<table>
<thead>
<tr>
<th>Study</th>
<th>ClinicalTrials.gov Identifier</th>
<th>Treatment Arms</th>
<th>Actual Enrollment</th>
<th>Objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELTEMI</td>
<td>NCT02808819</td>
<td>Benralizumab</td>
<td>446</td>
<td>To continue to characterize the safety profile of benralizumab and monitor the pharmacodynamic activity of the drug in these asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor BORA study.</td>
</tr>
<tr>
<td>ARIA</td>
<td>NCT02821416</td>
<td>Benralizumab vs placebo</td>
<td>45 (still recruiting)</td>
<td>To evaluate the effect of a fixed 30-mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in patients with mild atopic asthma challenged with an inhaled allergen.</td>
</tr>
<tr>
<td>SOLANA</td>
<td>NCT02869438</td>
<td>Benralizumab</td>
<td>235 vs placebo</td>
<td>To investigate the onset and maintenance of the effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in a body plethysmography substudy to further investigate the effect on lung function.</td>
</tr>
<tr>
<td>ANDHI</td>
<td>NCT03170271</td>
<td>Benralizumab vs placebo</td>
<td>630 (still recruiting)</td>
<td>To investigate the effect of benralizumab on the rate of asthma exacerbations, patient-reported quality of life and lung function during the 24-week treatment in patients with uncontrolled, severe asthma with eosinophilic phenotype. A subset of patients will be assessed for their ongoing chronic rhinosinusitis with nasal polyps.</td>
</tr>
<tr>
<td>MIRACLE</td>
<td>NCT03186209</td>
<td>Benralizumab vs placebo</td>
<td>666 (still recruiting)</td>
<td>To evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose ICSs plus a LABA with or without OCSs and additional asthma controllers.</td>
</tr>
</tbody>
</table>

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting \( \beta_2 \)-agonist; OCS, oral corticosteroid.
with nasal polyposis and by 0.102 L in patients without nasal polyposis. Similar trends were observed for efficacy measures of asthma symptoms (ACQ-6) and asthma-related quality of life (AQLQ[S]+12) [61]. Benralizumab also proved to be effective in hypereosinophilic syndrome with gastrointestinal involvement, a disease characterized by gastrointestinal eosinophilia and a peripheral eosinophil count ≥1500 cells/mm³ that does not always respond to corticosteroids or dietary intervention [62]. After 24 weeks of treatment with benralizumab, a dramatic reduction in eosinophil count was observed, and gastrointestinal symptoms improved in most patients [62].

8. Conclusions

Benralizumab is a monoclonal antibody against IL-5Rα that has proven to be effective and safe in the treatment of adults with uncontrolled severe eosinophilic asthma despite using high-dose ICSs and a LABA. Unlike other treatments targeting the IL-5 pathway used to manage eosinophilic asthma, benralizumab can reduce the activation and differentiation of eosinophils and basophils by preventing IL-5 from binding to its receptor and inducing apoptosis of these cells. These 2 functions are responsible for the rapid and almost complete decrease in eosinophil and basophil counts, which is greater than that described for mepolizumab and reslizumab. The decrease in blood eosinophils is accompanied not only by significantly reduced asthma exacerbations and use of OCSs, but also by improved lung function, asthma symptoms, asthma control, and quality of life, especially in patients with a baseline eosinophil count ≥300 cells/µL and a higher incidence of previous exacerbations. These results will be helpful in identifying patients with uncontrolled severe eosinophilic asthma who respond most effectively to benralizumab. These benefits were reached more quickly and with a longer dosing interval (every 8 weeks) than with mepolizumab or reslizumab. Benralizumab can be considered an effective and safe alternative in the treatment of patients with severe eosinophilic asthma. It could also be a possible treatment in other diseases involving eosinophils. Finally, the use of benralizumab in real life will provide new insights into the role of eosinophils in the body.

Acknowledgments

The authors wish to thank Dr. Fernando Sánchez Barbero and Content Ed Net (Madrid, Spain) for writing and editorial support during the preparation of this manuscript.

Funding

AstraZeneca Farmacéutica Spain S.A. funded medical writing support but made no contribution the contents or decision to publish.

Conflicts of Interest

Ignacio Dávila González has received payment for lectures from Allergy Therapeutics, ALK-Abelló, AstraZeneca, Diater, GlaxoSmithKline, Leti, Merck, Novartis, Stallergenes, and Teva. He has also received remuneration for providing consultancy services from ALK-Abelló, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Sanofi, and Stallergenes, as well as grants from Merck and Thermo Fisher Diagnostics.

Francisco Moreno Benítez has received payment for lectures or advisory services from AstraZeneca, Stallergenes, ALK-Abello, and Allergy Therapeutics.

Santiago Quirce has served as a consultant for AstraZeneca, Novartis, Sanofi, Teva, ALK-Abelló, Mundipharma, Boehringer Ingelheim, and GlaxoSmithKline and has received lecture fees from Chiesi, Novartis, GlaxoSmithKline, Leti, AstraZeneca, and Mundipharma.

References

34. Akar HH, Tahan F, Gungor HE. The association of forced expiratory volume in one second and forced expiratory flow at 50% of the vital capacity, peak expiratory flow parameters, and blood eosinophil counts in exercise-induced bronchospasm in children with mild asthma. Asia Pac Allergy. 2015;5:98-102.
53. Francisco Moreno Benítez
Unidad de Inmunología y Alergia
Clínica Lobatón
Avda. Fernández Ladreda, 9
11008 Cádiz, Spain
E-mail: dr.moreno@drlobaton.com